Relmada Therapeutics Inc

-1.01 (-4.09%)
Products, Regulatory

Relmada Therapeutics Provides Regulatory And Development Updates On Ongoing Late-Stage Clinical Program For Rel-1017

Published: 10/04/2021 12:58 GMT
Relmada Therapeutics Inc (RLMD) - Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-stage Clinical Program for Rel-1017 for Treatment of Major Depressive Disorder.
Relmada - FDA Confirms Co Not Required to Conduct 2-year Carcinogenicity Study, Tqt Cardiac Study in Humans to Support Approval Submissions for Rel-1017.
Relmada Therapeutics Inc - Actively Enrolling Patients in Reliance Iii, a Monotherapy Registrational Phase 3 Study.